Ranking Invest

Revolution Medicines, Inc.

Segmento: Healthcare Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Indicadores Básicos

Valor de Mercado

$ 6.81 Bi

IVR

0.08

IVR2

-0.23

Índices de Previsibilidade

Faturamento

0.69

Lucro

0.23

Margem

1.43

Índices de Tendência

Faturamento

-7.95

Lucro

-10.94

Margem

6.38

Índices de Endividamento

DIV/PAT

-0.10

DIV/L4T

0.29

Dívida Líquida

-$ 199.21 Mi

Patrimônio Líquido

$ 2.08 Bi

L4T

-$ 697.51 Mi

MM4T

-18.59%

Dívidas
Dividendos
Cotação: $36.54

Não há dados de histórico de dividendos para exibir.

Gráfico Lucro/Faturamento X Trimestre